Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Cancer Res. 2020 Apr 20;80(13):2833–2847. doi: 10.1158/0008-5472.CAN-19-2733

Figure 7.

Figure 7.

TGFβ/microRNAs axis is required for the down-regulation of ΔNp63 in other cancers including squamous cell carcinomas and bladder cancer. A-C, Representative immunoblots of cutaneous squamous cell carcinoma (cuSCC) lines COLO16, RDEB2, IC1 (A), bladder cancer cells (BLCA) 5637 (B), and head and neck squamous cell carcinoma (HNSCC) 22B (C) treated with TGFβ or with TGFβ plus TGFBRI inhibitor, LY2157299. Immunoblots were probed with the indicated antibodies. Actin was used as a loading control. D-F, qRT-PCR of the indicated microRNAs in COLO16 (D), RDEB2 (E) and IC1 (F) cells treated with or without TGFβ. Data are mean ± SD. n = 3. Asterisk indicates p <0.05. G-J, PCA analyses comparing a ΔNp63-transcriptional signature and a TGFβ-transcriptional signature in the indicated clusters, including C1-Lung Adenocarcinoma (G), C2-Lung Squamous Cell Carcinoma (H), C3-Luminal Breast Cancer (I) and C4-Basal Breast Cancer (J) subtypes.